Ticker brief
GSK GSK PLC-SPON ADR
Consumer, Non-cyclical · Pharmaceuticals
last close
$50.82
1 day
+1.1%
14 days
+2.6%
mkt cap
$107.5B
signals 14d
11
authors 14d
5
crowd 14d
+0.6σ
Options inteloptions-surface reads · latest available day per source
| metric | reading | context |
|---|---|---|
| IV — ATM 30d | 21% cheap · 6 pctile own 1y | IV/HV 0.65× (as of 2026-07-31) |
| Skew — 25Δ RR 30d | -0.074 11 pctile own 1y | puts bid vs calls (downside bid) |
| Net dealer OI (NDOI) | +0.05 thin | 5-session Δ +0.01 (as of 2026-07-16) |
| OI alarm | quiet | last alarm 2026-04-29 (z=6.8) |
Sentiment — last 14 days
daily mean sentiment, 2026-08-18 → 2026-08-27 · now -0.18 (−1 bearish … +1 bullish)
Who spoke5
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @fwpharma | B | +0.98 | 4 | +0.33 |
| @Asktraders1 | C | · | 4 | +0.49 |
| @StableBread | A | -1.09 | 1 | +0.00 |
| @GDXTrader | C | -2.82 | 1 | -0.20 |
| @BiopharmIQ | B | · | 1 | -0.15 |
Recent signals11of 11 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-08-27 | @BiopharmIQ | -0.15 | Details today's GILD FDA catalyst and positive competitive implications for its HIV franchise. | +1.1% | tweet ↗ |
| 2026-08-27 | @GDXTrader | -0.20 | GSK is approaching support but lacks confirmation of a bullish reversal | +1.1% | tweet ↗ |
| 2026-08-26 | @fwpharma | +0.25 | Reports research linking GSK's Shingrix vaccine with lower cardiovascular risk. | -1.2% | tweet ↗ |
| 2026-08-25 | @StableBread | +0.00 | Uses Teva patent precedents and biotech acquisitions to frame major strategic upside for RVPH. | -2.4% | tweet ↗ |
| 2026-08-24 | @fwpharma | +0.50 | Japan approved GSK's hepatitis B therapy following an unprecedented reported cure rate. | -1.9% | tweet ↗ |
| 2026-08-24 | @Asktraders1 | +0.50 | Reports Hibsago's first global approval in Japan and a major efficacy claim despite slightly lower GSK shares. | -1.9% | tweet ↗ |
| 2026-08-24 | @Asktraders1 | +0.45 | Summarizes two regulatory wins for GSK and notes a muted market reaction. | -1.9% | tweet ↗ |
| 2026-08-24 | @Asktraders1 | +0.50 | Reports FDA priority review acceptance and phase-trial data supporting two GSK pipeline programs. | -1.9% | tweet ↗ |
| 2026-08-24 | @Asktraders1 | +0.50 | Reports FDA priority review for Jemperli and Japanese approval for Hibsago while GSK shares edged lower. | -1.9% | tweet ↗ |
| 2026-08-21 | @fwpharma | +0.30 | GSK started Phase III studies of TSLP blockade for COPD. | -3.0% | tweet ↗ |
| 2026-08-18 | @fwpharma | +0.25 | GSK acquired full rights to Chugai's experimental anti-dengue antibody. | -0.6% | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.